Table 5.
TNFα | Stroke cases | Stroke controls | OR (5% CI) with adjustments |
||
---|---|---|---|---|---|
Tertiles | Model 1 | Model 2 | Model 3 | ||
Range (pg/mL) | |||||
2.07–45.30 | 78 | 161 | 1.12 (0.75, 1.66) | 1.15 (0.76, 1.74) | 1.11 (0.73, 1.69) |
1.40–2.06 | 80 | 155 | 1.19 (0.81, 1.75) | 1.13 (0.75, 1.69) | 1.11 (0.74, 1.66) |
0.03–1.39 | 76 | 172 | 1 | 1 | 1 |
Total | 234 | 488 | p = 0.567 | p = 0.516 | p = 0.631 |
OR (95% CI) | |||||
Continuous | Model 1 | Model 2 | Model 3 | ||
1 log2 (TNFα)b | 234 | 488 | 1.15 (0.95, 1.39) | 1.14 (0.93, 1.40) | 1.13 (0.92, 1.38) |
Model 1 = age, gender and region.
Model 2 = model 1 + smoking, alcohol, physical activity, history of diabetes, BMI, SBP, DBP, TC, HDL.
Model 3 = model 2 + IL-6 + CRP.
Complete case analysis sample. Tertiles based on control group. p-value for test for trend over tertiles.
OR of MI per 1 log2 increase in log 2(TNFα), i.e. doubling of TNFα.